DocSym
β
Searchsearch
Search
(G23.2) Multiple system atrophy, parkinsonian type [msa-p]
More details coming soon
111 647 in individuals diagnosis multiple system atrophy, parkinsonian type [msa-p] confirmed
45 439 deaths with diagnosis multiple system atrophy, parkinsonian type [msa-p]
41% mortality rate associated with the disease multiple system atrophy, parkinsonian type [msa-p]
Diagnosis multiple system atrophy, parkinsonian type [msa-p] is diagnosed Men are 19.75% more likely than Women
66 848
Men receive the diagnosis multiple system atrophy, parkinsonian type [msa-p]
23 581 (35.3 %)Died from this diagnosis.
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
44 799
Women receive the diagnosis multiple system atrophy, parkinsonian type [msa-p]
21 858 (48.8 %)Died from this diagnosis.
Risk Group for the Disease multiple system atrophy, parkinsonian type [msa-p] - Men and Women aged 65-69
In Men diagnosis is most often set at age 10-89
Less common in men the disease occurs at Age 0-9, 90-95+Less common in women the disease occurs at Age 0-1, 95+
In Women diagnosis is most often set at age 0-94
Disease Features multiple system atrophy, parkinsonian type [msa-p]
Absence or low individual and public risk
Multiple system atrophy, parkinsonian type [msa-p] - what does this mean
Multiple system atrophy, parkinsonian type (msa-p) is a rare neurological disorder caused by the progressive degeneration of nerve cells in the brain which leads to difficulty with balance, coordination, and movement as well as other autonomic functions. the cause of msa-p is unknown, but it is thought to be related to a combination of genetic and environmental factors.
What happens during the disease - multiple system atrophy, parkinsonian type [msa-p]
Msa-p is a progressive neurodegenerative disorder caused by the degeneration of specific areas of the brain, such as the substantia nigra and the cerebellum. this leads to the destruction of dopaminergic neurons, resulting in a decrease in dopamine production and a disruption of the normal balance of neurotransmitters. this leads to a wide range of motor and non-motor symptoms, including those associated with parkinson's disease, such as muscle rigidity, tremor, and imbalance.
Clinical Pattern
More details coming soon
How does a doctor diagnose
- Clinical evaluation and history taking
- Neurological examination
- Lab tests including complete blood count, liver function tests, thyroid function tests, vitamin B12 and folic acid levels, and urinalysis
- Imaging tests such as MRI or CT scan of the brain and spine
- Electrodiagnostic tests such as electromyography and nerve conduction studies
- Urine tests for dopamine metabolites
- Genetic testing
- Cerebrospinal fluid analysis
- Tilt table test
- Cardiac tests
Treatment and Medical Assistance
Main goal: To reduce the symptoms of MSA-P and improve the quality of life.
- Prescribing medications to reduce symptoms, such as muscle spasms, tremors, and difficulty with balance and coordination.
- Physical therapy to help with balance and coordination.
- Occupational therapy to help with daily living activities.
- Speech therapy to help with speaking, swallowing, and communication.
- Psychological counseling to help with depression and anxiety.
- Nutrition counseling to help with maintaining a healthy diet.
- Social support to help with adjusting to lifestyle changes.
33 Days of Hospitalization Required
Average Time for Outpatient Care Not Established
Multiple system atrophy, parkinsonian type [msa-p] - Prevention
Prevention of msa-p is not possible as it is a progressive neurological disorder with no known cause. however, lifestyle modifications such as regular exercise, a healthy diet, maintaining a healthy weight, and avoiding smoking and excessive alcohol consumption may help reduce the risk of developing msa-p.